{"id":"NCT00382408","sponsor":"Duramed Research","briefTitle":"A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2007-12","completion":"2007-12","firstPosted":"2006-09-29","resultsPosted":"2012-05-25","lastUpdate":"2017-04-10"},"enrollment":4040,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Tract Diseases"],"interventions":[{"type":"BIOLOGICAL","name":"DR-5001","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Vaccine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral DR-5001 in reducing the attack rate of febrile acute respiratory disease caused by type-4 and type-7 adenovirus as well as determine its immunogenicity.","primaryOutcome":{"measure":"Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort","timeFrame":"Day 0 - Day 56","effectByArm":[{"arm":"Vaccine","deltaMin":1,"sd":null},{"arm":"Placebo","deltaMin":48,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"17 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":1009},"commonTop":["HEADACHE","UPPER RESPIRATORY TRACT INFECTION","ARTHRALGIA","PHARYNGOLARYNGEAL PAIN","NASAL CONGESTION"]}}